• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Aldagen's Products Isolate Human Adult Stem Cells That Can Regenerate Vascular Function

Posted on: Monday, 12 December 2005, 09:00 CST

Aldagen, Inc. today announced that researchers from the Washington University School of Medicine presented results demonstrating that the unique human adult stem cell population isolated by Aldagen's products (ALDHbr cells) are able to regenerate vascular function in a preclinical model of ischemic injury. The work, entitled "Bone marrow-derived aldehyde dehydrogenase expressing cells possess endothelial progenitor function in addition to hematopoietic repopulating ability, and aid in blood flow recovery after acute ischemic injury," was presented at the 47th Annual Meeting of the American Society of Hematology in Atlanta, Georgia.

To test the neoangiogenic function of ALDHbr cells in vivo, the Washington University group performed femoral artery ligation in the hind limb of NOD/SCID B2M null mice, and transplanted purified ALDHbr cells from human bone marrow via the tail vein within 24 hours of ischemic injury. The recovery from acute ischemic injury was calculated by the ratio of blood flow in the ischemic versus the non-ischemic leg by laser Doppler perfusion imaging, performed twice weekly over 28 days. In comparison to PBS-injected control mice (n=6), mice transplanted with ALDHbr cells (n=7) showed enhanced blood flow to the ischemic limb by day 7 post-injection (p less than 0.05). This enhanced recovery of blood flow was maintained throughout the 28-day monitoring period.

"These findings may have implications in the development of stem cell therapies for the treatment of patients with acute vascular injury or peripheral vascular disease," commented Dr. David Hess, the senior author of the abstract who has studied ALDHbr cells extensively.

"This preclinical study illustrates the significant therapeutic potential of adult stem cells isolated with our technology and we expect to initiate multiple clinical trials in the next six months in areas were vascular regeneration would represent a novel therapeutic approach," added Ed Field, President and CEO of Aldagen.

About Aldagen, Inc.

Aldagen's proprietary products identify and isolate unique populations of adult stem cells with the potential to revolutionize treatments of cardiovascular disease and degenerative diseases. The Company is now testing these products in clinical trials. To learn more about Aldagen's products for preparing optimal cell populations for adult stem cell therapy, the Company invites you to visit its website at www.aldagen.com.

Source: Business Wire

More News in this Category